Mycoplasma Testing Market Segmentation, Challenges and Opportunities to 2027


Posted November 30, 2020 by supii623

An extensive study of the product application and services conducted by subject matter experts assessing the market will help product owners to make a wise decision.
 
The global market size for Mycoplasma Testing was estimated at USD 609.39 million in 2019 and is projected to hit USD 1.59 billion by 2027, at a CAGR of 12.6 percent, according to the latest review of Reports and Data. Mycoplasma is the smallest recognised species of bacteria that has evolved from Gram-positive bacteria due to de-generative evolution. The bacterial mycoplasma cell has a missing cell wall and can be either saprotrophic or parasitic. While there are almost 200 distinct forms of mycoplasma bacteria, most of them are harmless. In humans, just 5 out of 200 cause serious infections.




In the human body, various mycoplasma species cause various diseases. Mycoplasma pneumonia, for instance, affects the throat and lungs, while urethra infection is linked to Mycoplasma genitalium. Mycoplasma testing is used in patients to investigate current or past infections with mycoplasma. Mycoplasma microbes in the genitourinary tract, throat, or respiratory tract of the patient may exist as healthy flora. In addition, mycoplasma bacterial cells are resistant to various traditional antibiotics due to the absence of cell walls. Testing for mycoplasma plays an important role in cell culture and this testing, including cell banks, viral seed stocks, and final products, is necessary for any phase of product growth.

Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/2129

The growth of the mycoplasma testing market is motivated by important research and development activities in the academic and bio-pharmaceutical industries, an increased occurrence of mycoplasma infections and contamination of cell culture. During cell culture, mycoplasma can spread easily through droplets and is hard to detect under a microscope. Therefore, to be identified, they require unique tests. Growing expenditure by leading market players in the healthcare sector to enhance consumer loyalty and achieve technological innovations is expected to stimulate the global mycoplasma testing market.




The demand for mycoplasma testing is also driven by increased acceptance of mycoplasma testing in the microbiology field, increased occurrence of water pollution-related infections, increased public and private sector investment in the healthcare industry, and greater understanding of mycoplasma bacterial infections. However, minimal awareness among patients and clinicians of mycoplasma infection and difficulties associated with its identification are expected to impede the growth of the market.

The demand for mycoplasma testing is increasing at a phenomenal 13 percent CAGR in Asia Pacific, followed by 12.8 percent and 12.5 percent CAGR in North America and Europe, respectively. Growing government funding, combined with high R&D investments, are key drivers of market growth in these regions.

Key participants in the mycoplasma testing market include:

Thermo Fisher Scientific Inc.
Lonza Group Ltd.
Merck KGaA
Roche Diagnostics
American Type Culture Collection
Bionique Testing Laboratories, Inc.
InvivoGen
PromoCell GmbH
Norgen Biotek Corp.
GenBio
Meridian Bioscience, Inc.
Savyon Diagnostics

Mycoplasma Testing Market: Segmentation

 

For the purpose of this report, Reports and Data has segmented the mycoplasma testing market on the basis of product type, technology type, application type, end use, and region:

Product Type (Revenue, USD Million; 2017–2027)

Instruments
Kits & Reagents
PCR Assay
Nucleic Acid Detection
Elimination Kits & Reagent
Stains
Standards & Controls
Others
Services
Others

Technology Type (Revenue, USD Million; 2017–2027)

PCR
ELISA
Direct Assay
Indirect Assay
DNA Staining
Microbial Culture Techniques
Enzymatic Methods
Others

Application Type (Revenue, USD Million; 2017–2027)

Cell Line Testing
Virus Testing
End of Production Cells Testing
Others

End Use (Revenue, USD Million; 2017–2027)

Pharmaceutical Companies
Cell Banks
Others

Regional Outlook (Revenue in USD Million; 2017–2027)

North America
S.
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of the Europe
Asia Pacific
China
India
Japan
Rest of Asia-Pacific
Middle East & Africa
Latin America
Brazil

Thank you for reading our report. The customization of the report is available as per your research needs. Please get in touch with us, and our team will ensure you get the report tailored as per your requirements.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Supriya
Country United States
Categories Health , Home Business , Human Resources
Tags mycoplasma testing market , mycoplasma testing market demand , mycoplasma testing market size , mycoplasma testing market trends
Last Updated November 30, 2020